
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is experiencing significant growth, as indicated by a 20.6% year-over-year increase in top-line revenue, reaching $252.4 million, surpassing consensus expectations. The company is well-positioned for future expansion with a robust product pipeline and the recent FDA clearance for Type 2 diabetes, effectively doubling its addressable market in the U.S. Furthermore, customer satisfaction and strong retention rates underpin a solid foundation for sustained, double-digit revenue growth, supported by increasing warranty renewals and supply sales.
Bears say
Tandem Diabetes Care has experienced substantial operating losses since its inception, casting doubt on its ability to achieve sustained profitability. The company's recent guidance for 2025 indicates weaker-than-expected sales trends, challenges with expanding market share for its Mobi pump, and potential risks from competitive pressures and reimbursement issues, all contributing to a negative outlook. Additionally, the company's gross margins fell short of consensus expectations, and the stock experienced a significant decline of approximately 19% in after-hours trading, further reflecting market concerns about its financial health and growth prospects.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares